Abstract
Nabumetone, a new nonsteroidal anti-inflammatory drug (NSAID) has been investigated in several clinical trials and over 18 000 patients in a drug monitoring study (Lemmel & Stroehmann 1988). An elimination half-life of 22 hours permits oncedaily dosing. The standard recommended dose is 1000mg for patients under 65 years and 500mg for patients over 65. Elderly patients, especially females, represent a subgroup with an increased risk for NSAID therapy because of frequent co-medication, decreased gastrQintestinal tolerance and potential impaired renal and hepatic function. Furthermore, elderly patients with chronic rheumatic disease often present with a higher incidence of severe gastrointestinal side effects due to previous NSAID treatment, and an eventual history of gastroduodenal ulcers or gastropathy. The objectives of the present study were:
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
